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ABSTRACT 
Introduction: Metabolic bone diseases are disorders of bone strength, usually caused by abnormalities of minerals (such as calcium or 
phosphorus), vitamin D, bone mass and/or structure. The most common metabolic bone disease is osteoporosis. It is a progressive bone 
disease that is characterized by a decrease in bone mass and density which can lead to an increased risk of fracture. This review was aimed 
to summarize a plenty of literatures related to the impact of Receptor Activator of Nuclear factor k-B (RANK)/RANK 
Ligand/Osteoprotegrin (OPG) system on bone metabolic diseases and therapeutic agents targeting this system.  
Method: Data were collected from several legitimate data bases and services such as Pubmed, Pub med central, Medline, Hinari, Scopus, 
and other data base sources like Crossref, and Google scholar with the help of key words (RANK/RANKL/OPG system, metabolic bone 
diseases etc.). The data collection was carried out from July to October, 2016. Important data on the topic of interest were filtered properly. 
Review body: The role of RANK/RANKL/OPG system is well characterized within bone, where RANKL-RANK signaling mediates 
osteoclastogenesis, osteoclast activation and bone resorption via paracrine signaling between osteoblast and osteoclast cells. OPG produced 
by osteoblast and stromal cells in bone acts as a natural RANKL antagonist (decoy receptor) that intereferes with RANKL-RANK binding 
and hence prevents osteoclast differentiation and activation. This system and its interaction with various cytokines and calciotropic 
hormones in the regulation of osteoclastogenesis has led to a new era for further understanding of the pathophysiology of several disorders 
of bone metabolism including osteoporosis, primary bone tumors and rheumatoid arthritis. The system has also resulted in the recognition of 
several rare genetic disorders of bone mineral metabolism such as paget's disease, familial expansile osteolysis and osteopetrosis.  
Conclusion: Since this cytokine system plays a major role in the pathogenesis of many disorders, several therapeutic agents targeting this 
system are being developed. Among them, denosumab, a monoclonal antibody against RANKL, is clinically approved for the treatment of 
osteoporosis and cancer-related bone diseases.   
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INTRODUCTION  
Bone metabolism comprises the processes of bone 
formation and bone resorption, the key actions by which 
skeletal mass, structure and quality are accrued and 
maintained throughout life. In the mature skeleton, 
anabolic and catabolic actions are mostly balanced due 
to the tight regulation of the activity of bone forming 
cells (osteoblasts) and bone resorbing cells (osteoclasts) 
through circulating osteotropic hormones and locally 
active cytokines.
1
  
Osteoblasts are derived from mesenchymal stem cells, 
and their differentiation is induced by several specific 
transcription factors, including core-binding factor α1 
and osterix as well as by the bone morphogenic proteins 
(BMP-2, BMP-4, and BMP-7). Mature osteoblasts 
synthesize and secrete type I collagen, the major 
structural protein in bone matrix. Osteoblasts also 
secrete non-collagen proteins including osteocalcin, 
osteopontin, and bone sialoprotein, as well as cytokines 
including insulin like growth factor-1 (IGF-1), IL-1, and 
IL-6. 
1, 2 
Osteoclasts are hematopoietic in origin and 
derive from granulocyte-macrophage progenitor cells. 
Osteoclastogenesis requires stimulation by macrophage-
colony stimulating factor (M-CSF) and the binding of 
RANKL, expressed on osteoblasts, to RANK receptor 
on the osteoclast precursors. Osteoclast recruitment and 
activity are each highly regulated by cells of the 
osteoblast lineage. 
3, 4 
METABOLIC BONE DISEASES  
Metabolic bone diseases (MBD) are disorders of bone 
strength, usually caused by abnormalities of minerals 
(such as calcium or phosphorus), vitamin D, bone mass 
and/or structure. MBD includes several bone diseases 
including osteoporosis, primary bone tumors, rare 
genetic disorders and inflammatory bone diseases 
(Table 1). The most common MBD is osteoporosis 
which is a progressive bone disease characterized by a 
decrease in bone mass and density which can in turn 
lead to an increased risk of fracture.
5,6 
 In osteoporosis, 
the bone mineral density (BMD) is reduced, bone micro 
architecture deteriorates, and the amount and variety of 
proteins in bone are altered. It is defined by the World 
Health Organization (WHO) as a bone mineral density 
of 2.5 standard deviations or more below the mean peak 
bone mass (average of young, healthy adults) as 
measured by dual-energy X-ray absorptiometry. The 
disease may be classified as primary type 1, primary 
type 2, or secondary. The form of osteoporosis most 
common in women after menopause is referred to as 
primary type 1 or postmenopausal osteoporosis. Primary 
type 2 osteoporosis or senile osteoporosis occurs after 
age 75 and is seen in both females and males at a ratio 
of 2:1. Secondary osteoporosis may arise at any age and 
affect men and women equally. This form results from 
chronic predisposing medical problems or disease, or 
prolonged use of drugs such as glucocorticoids, where 
the disease is called glucocorticoid-induced 
osteoporosis. 
6-9
 
Osteoporosis is a major and growing public health 
problem in developed nations. Many women (30-50%) 
and men (15-30%) suffer a fracture related to it. 
Characteristic sites of fracture include vertebral bodies, 
the distal radius, and the proximal femur, but 
osteoporotic individuals have generalized skeletal 
fragility, and fractures at sites such as ribs and long 
bones also are common.
6,10 
Coming to primary bone tumors, multiple myeloma is 
the most common primary malignant bone tumor but is 
often considered a marrow cell tumor within the bone 
rather than a bone tumor. Osteosarcoma (osteogenic 
sarcoma) is the 2nd most common primary bone tumor 
and is highly malignant. It is most common among 
people aged 10 to 25 years, although it can occur at any 
age. Osteosarcoma produces malignant osteoid 
(immature bone) from tumor bone cells. Malignant giant 
cell tumor, which is rare, is usually located at the 
extreme end of a long bone. 
7, 11
 
Regarding genetic disorders of bone metabolism, Paget's 
disease is characterized by single or multiple sites of 
disordered bone remodeling. The etiology of the disease 
is uncertain but is thought to be the result of infection 
with the measles virus of the paramyxovirus family. It 
affects up to 2-3% of the population >60 years of age. 
The primary pathologic abnormality is increased bone 
resorption followed by exuberant bone formation.
12
 
Osteopetrosis is also a rare polygenic disorder of 
generalized increased bone mass due to decreased 
osteoclastogenesis and bone resorption. 
13 
 
Table 1: Summary of metabolic bone diseases 
Metabolic bone diseases  Sub classes  References 
Osteoporosis  Postmenopausal osteoporosis 
5-10 
Drug-induced osteoporosis 
Immobilization-induced osteoporosis 
Hyperparathyroidism induced osteoporosis  
Primary malignant bone tumors Osteo-sarcoma 
7,11 
Multiple myeloma   
Giant cell tumor of the bone 
Rare genetic disorders  Juvenile Paget’s disease 12,13 
Expansile skeletal hyperphosphatasia 
Familial expansile osteolysis 
Osteopetrosis 
Inflammatory bone diseases  Rheumatoid arthritis  
5-7 
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METHOD  
Data were collected from several legitimate data base 
sources and services such as Pubmed, Pub med central, 
Medline, Hinari, Scopus, and other data bases like 
Cross-ref, Socolar and Google scholar with the help of 
key words such as RANK/RANKL/OPG triad system, 
bone metabolism and associated disorders linked to this 
system as well as potential therapeutic approaches under 
study. Important data related to the topic of interest were 
filtered accordingly. Time frame was also adjusted to 
capture all valuable information regarding the impact of 
RANK/RANKL/OPG system on several MBDs as well 
as current potential therapeutic agents targeting this 
signaling pathway using different search engines. This 
review was conducted from July 2016 to October 2016 
G.C.  
The role of RANK/RANKL/OPG molecular triad 
system at glance  
The RANK/RANKL/OPG molecular triad system has 
been shown to influence several biological and 
pathophysiological processes throughout the body 
including bone metabolism, immune system, mammary 
gland development and cancer.
14,15
 RANK/RANKL/ 
OPG molecular signaling plays an important role in 
lymph node development, lymphocyte differentiation, 
dendritic cell survival, T-cell activation, and tolerance 
induction (Figure 1). The RANKL/RANK axis also 
have direct osteoclast-independent effects on tumor cell 
development.
16 
RANK has also been shown to play a 
role in the thermoregulation signaling in females, which 
seems to be regulated by ovarian sex hormones. This 
key role of the RANK-RANKL system may link the 
osteoporosis and hot flashes seen as symptoms of 
hormonal changes in post-menopausal women. 
17, 18 
OPG-deficient mice exhibited medial calcification of the 
aorta and a renal artery suggesting that regulation of 
OPG, and its signaling pathway play a role in vascular 
calcification and is a risk factor for development of 
atherosclerosis.
19
 A study conducted in diabetic Charcot 
neuropathy (DCN) patients showed that RANK/ 
RANKL/OPG signaling was involved in patients with 
DCN and played a role in vascular calcification.
20
 
 
Figure 1: The role of RANK/RANKL/OPG system at glance 
The role of RANK/RANKL/OPG molecular triad 
cytokine system is well characterized within bone, 
where RANKL/RANK signaling mediates 
osteoclastogenesis and bone resorption and OPG 
prevents RANK ligand interaction with RANK and 
hence prevent osteoclast differentiation and activation 
(Figure 2).
21 
RANKL induces the differentiation of 
osteoclast precursor cells and stimulates the resorption 
process and survival of mature osteoclasts. The TRAF 
adaptor proteins play an important role in the initial 
event of the signal transduction pathway induced by 
RANK. TRAFs 1, 2, 3, 5 and 6 are known to bind 
through the conserved TRAF domain to RANK.
22, 23
 
 
Figure 2: overview of RANK/RANKL/ OPG system in 
bone metabolism (OC=osteoclast) 
The RANK/RANKL/OPG system in metabolic bone 
diseases  
The discovery of the RANK/RANKL/OPG system and 
its interaction with various cytokines and calciotropic 
hormones in the regulation of osteoclastogenesis has led 
to a new era of the pathophysiology of several disorders 
of bone metabolism.
24
 An imbalance of RANKL and 
OPG with an enhanced RANKL/OPG ratio favors 
osteoclast differentiation and activation and promotes 
bone loss. Systemic factors that enhance the 
RANKL/OPG ratio include glucocorticoids, 
immunosuppressants, estrogen deficiency, and 
continuous exposure to PTH. By contrast, the 
RANKL/OPG ratio is reduced by estrogens (17β-
estradiol, raloxifene, genistein) and mechanical strain.
25
 
It became evident that many clinically relevant 
metabolic bone diseases in humans, including 
inflammatory bone diseases (e.g., rheumatoid arthritis), 
malignant bone tumors (e.g., myeloma or osteolytic 
metastases) and different forms of osteoporosis are 
related to alterations of the RANK/RANKL/OPG 
system. This system is also known to be involved in rare 
genetic disorders of bone metabolism, such as paget's 
disease and familial expansile osteoporosis. 
25,26
  
Osteoporosis  
Estrogens are known to regulate various cytokines in the 
bone microenvironment that regulate OC function. 
Sisay et al                                                     Journal of Drug Delivery & Therapeutics. 2016; 6(6)31-39                     34 
© 2011-16, JDDT. All Rights Reserved                                            ISSN: 2250-1177                                                    CODEN (USA): JDDTAO 
Among which the RANK/RANKL/OPG system plays a 
significant role in estrogen induced bone remodeling. 
27 
Estrogen deficiency causes both the early and late forms 
of osteoporosis in postmenopausal women.  Since the 
discovery of RANK/RANKL/OPG system as a final 
pathway in osteoclast formation and differentiation, 
studies have confirmed the key role of this pathway in 
the pathogenesis of postmenopausal osteoporosis. In 
vitro experiments in human osteoblastic cell lines have 
shown a dose- and time-dependent increase in OPG 
mRNA in response to 17β-estradiol. Up-regulation of 
OPG is expected to decrease the interaction of RANKL 
with RANK in vivo and, hence, reduce osteoclastic bone 
resorption. Furthermore, the administration of OPG to 
ovariectomized rats was shown to prevent bone loss. 
28 
Osteoblastic cells express both estrogen receptors, ER- α 
and ER-β. 17β-estradiol increased OPG gene expression 
and protein secretion through a transcriptional 
mechanism in mesenchymal cells and mature 
osteoblastic cell lines that had been stably transfected 
with the ER-α·, while no such effect was observed in 
cells transfected with the ER-β.  Phytoestrogens  such  
as  genistein  are  also able to enhance osteoblastic OPG 
production through ERα-dependent mechanisms and 
concurrently suppress RANKL gene  expression  which  
is  associated  with  an  inhibition  of osteo-
clastogenesis.
29,30
 Another mechanism how estrogens 
interact with the OPG/RANKL/RANK system is 
associated with 17β-estradiol iduced repression of JNK 
activity, a critical down-stream signal of RANK 
pathway. This may attenuate the responsiveness of 
osteoclastic RANK receptors, thus diminishing the 
biological effects of RANKL.
31 
Long term systemic glucocorticoid administration 
results in rapid bone loss due to a combined effect of 
decreased bone formation and enhanced bone 
resorption. While increased osteoblastic apoptosis and 
decreased osteoblastic synthesis of bone matrix proteins  
largely  account  for  decreased  osteoblastic  activity,  
an enhanced  RANKL/OPG  ratio  may  be  a  crucial  
paracrine mechanism for increased bone resorption.
32
 
Glucocorticoids were found to suppress OPG mRNA 
expression and protein secretion and up-regulate 
RANKL mRNA expression in various osteoblastic cell 
models independently  of  the  stage  of  differentiation  
and  the  baseline  level  of expression. Glucocorticoid-
response elements have been detected in the mouse 
RANKL gene, suggesting a regulatory mechanism 
through enhanced transcriptional activity. 
33, 34
 Studies 
of patients treated with glucocorticoids for both Crohn’s 
disease and chronic glomerulonephritis demonstrated a 
significant increase in the serum RANKL/OPG ratio. 
This change correlated with increased levels of urinary 
and serum markers of bone resorption and with a fall in 
BMD.
35, 36
 Another study demonstrated higher OPG 
serum levels in patients with Cushing’s syndrome 
compared to healthy controls, and OPG serum levels 
were significantly correlated with serum cortisol level. 
This indicates a difference between exogenous and 
endogenous glucocorticoid exposure or may be a 
mechanism to compensate bone loss in long-standing 
high cortisol levels.
37
  
Immunosuppressants that are commonly used after 
allogeneic transplantation have been implicated in the 
pathogenesis of transplantation-associated osteoporosis. 
Different immunosuppressive agents concurrently 
enhance RANKL mRNA expression and suppress OPG 
mRNA levels and OPG protein secretion in 
undifferentiated human mesenchymal bone marrow 
stromal cells which appear to be rather susceptible to the 
effects of these drugs.  By contrast, mature osteoblasts 
are relatively resistant against these drugs. 
38 
RANK/RANKL/OPG system has implicated as a 
paracrine mediator of mechanical strain on bone 
metabolism.  Mechanical strain applied to murine 
primary stromal cells decreased RANKL mRNA levels 
by approximately 40% which was paralleled by a 50% 
reduction of osteoclast formation. More detailed follow-
up studies indicated that RANKL inhibition following 
mechanical strain critically depends on the activation of 
the extracellular regulated kinase (ERK) 1/2 pathway.
39, 
40
 Blockade of RANKL using parenteral administration 
of OPG has been used to reduce bone loss associated 
with immobilization in sciatic nerve damage and tail-
suspension experiments. In a murine model of sciatic 
nerve crush, OPG administration reduced femoral bone 
loss in a dose-dependent manner. Similarly, in the 
murine tail suspension model, OPG treatment mitigated 
bone loss by decreasing femoral endocortical resorption 
by 24%. 
41, 42
 
Continuously increased and unregulated serum PTH 
concentrations, as presented in hyperparathyroidism, 
resulted in increased bone resorption and bone loss. In 
vitro, PTH was found to stimulate RANKL mRNA 
levels and to decrease OPG production in osteoblastic 
cells and to increase the RANKL/OPG ratio. All of 
these changes were associated with increased osteoclast 
formation.
43 
The potential molecular basis for the dual 
clinical effects of PTH, catabolic effect on continuous 
exposure and anabolic effect on intermittent exposure, 
was suggested by an elegant in vitro model.  While 
continuous PTH exposure enhanced the RANKL/OPG 
ratio by up to 25-fold and stimulated osteoclastogenesis, 
intermittent PTH exposure stimulated IGF-1 mRNA, an 
anabolic skeletal growth factor.  What is more, treatment 
of rats with PTH also decreased OPG mRNA levels in 
rat femur metaphyseal and diaphyseal bone in vivo.
44,45
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Table 2: Summary of osteoporosis types linked with RANK/RANKL/OPG system  
Types of osteoporosis  Linkage to RANK/RANKL/OPG system  Ref. 
Postmenoposal  
osteoporosis 
In vitro experiments in human osteoblastic cell lines have shown a dose- and time-
dependent increase in OPG mRNA in response to 17β-estradiol 
28 
Administration  of OPG to ovariectomized rats was shown to prevent bone loss 
28 
17β-estradiol iduced repression of JNK activity, a critical down-stream signal of 
RANK pathway 
31 
Phytoestrogens  are  also able to enhance osteoblastic OPG production 
29, 30 
Drug induced  
osteoporosis 
Glucocorticoids were found to suppress OPG mRNA expression 
33, 34 
Glucocorticoids increase in the serum RANKL/OPG ratio 
35, 36 
immunosuppressive agents concurrently enhance RANKL mRNA expression and 
suppress OPG mRNA levels 
38 
Immobilization induced 
osteoporosis 
In a murine model of sciatic nerve crush, OPG administration reduced femoral 
bone loss in a dose-dependent manner 
41 
In the murine tail suspension model, OPG treatment mitigated bone loss by 
decreasing femoral endocortical resorption 
42 
Hyperthyroidism 
induced  osteoporosis 
In vitro, PTH was found to stimulate RANKL mRNA levels and to decrease OPG 
production in osteoblasts (increase the RANKL/OPG ratio) 
43 
PTH also decreased OPG mRNA levels 
44, 45 
 
Rheumatoid arthritis  
Rheumatoid arthritis (RA) is a chronic inflammatory 
condition associated with progressive destruction of the 
articular synovial lining. T cell invasion of the synovium 
plays a crucial role in the obliteration of the articular 
cartilage and adjacent bone. Furthermore, fibroblast-like 
synovial cells have been shown to play a role in this 
process. It has been demonstrated that T cells express 
RANKL and that there is over-expression of RANKL 
mRNA in the synovium of RA patients at the site of bone 
resorption Elevated serum levels of soluble RANKL and 
OPG have been demonstrated in patients with RA, and 
these factors normalize after treatment with anti-TNF 
therapy.
46,47
 A recent study showed that Stromal cell-
derived factor 1 (SDF-1) is a chemokine that is involved 
in the bone-destructive process in RA and bony 
metastasis in malignancy.  It induces osteoclastogenesis 
directly and indirectly via up-regulating RANKL 
expression in RA synovial fibroblasts and CD4+ T cells, 
and that this is mediated by TNFα. The axis of SDF-1 
and RANKL is a potential therapeutic target for RA-
associated bone destruction.
48 
Primary malignant bone tumors 
Osteosarcoma, the most frequent primary malignant bone 
tumor, is defined as a malignant tumor originates from 
mesenchymal cells characterized by the direct malignant 
osteoid and/or woven bone formation by tumor cells.
49
 It 
is strongly associated with abnormal RANKL/RANK/ 
OPG balance that leads to pathological bone fractures. 
Grimaud et al. demonstrated an increase in serum 
RANKL/OPG ratio in the patients with high grade 
osteosarcoma.
50 
OPG treatment achieved not only the 
prevention of osteosarcoma-induced osteolysis but also 
the inhibition of associated tumor development that 
improved survival rate in OPG-treated animals. The study 
failed to demonstrate direct effect of OPG on tumor cells 
survival since it also blocks TNF related apoptosis 
inducing ligand (TRAIL).
51
 
Multiple myeloma (MM) is a plasma cell malignancy that 
develops in the bone marrow and characterized by the 
development of osteolytic bone lesions associated with 
bone pain, hypercalcemia and pathological fractures. 
Three cell types are involved in this pathology:- myeloma 
cells, bone marrow stromal cells and osteoclasts. 
Imbalance in the RANK/RANKL/OPG system was 
suggested as an alternative mechanism for enhanced 
osteoclastogenesis in bone loss associated with multiple 
myeloma. Derangements in the RANK/RANKL/OPG 
system may be due to alterations in RANKL production 
and/or increased lysosomal degradation of OPG. 
Increased RANKL expression in multiple myeloma may 
be due to its direct production by myeloma cells or its 
indirect production through the increased synthesis of IL-
7, which then over express RANKL in stromal cells.
52 
Giant cell tumor of bone (GCTB) is an osteolytic, usually 
benign neoplasm characterized by infiltration with 
osteoclast-like giant cells, and the osteoclast 
differentiation factor, RANKL is heavily involved in its 
pathogenesis. The stromal cells within GCTB samples 
had increased RANKL/OPG ratio compared to that of 
non-osteolytic bone tumors. 
53 
Rare genetic disorders  
Discovery of the RANK/RANKL/OPG system has led to 
recognition of several rare genetic disorders of bone 
mineral metabolism.  
Mutations in the OPG gene can cause abnormalities in 
the ligand-binding properties of OPG, resulting in its 
inactivation and a disorder with diverse phenotypic 
presentations.  
 Juvenile Paget’s disease (JPD) is a rare autosomal 
recessive disorder that presents in early childhood 
with bone deformities, fractures, hearing deficits, and 
dental abnormalities of variable severity. The disorder 
can be due to an inactivating mutation in the OPG 
gene (TNFRSF11B), localized to chromosome 
8q24.2. Missense mutations in the cysteine residues of 
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OPG are predicted to interfere with its ligand-binding 
domain and are responsible for the most severe 
phenotype of JPD. In more intermediate forms of 
JPD, missense mutations in residues other than 
cysteine are present in the ligand-binding region of 
the OPG. In addition, an insertion-deletion in exon 5 
of this gene has been associated with a milder form of 
the disease. All of these mutations lead to unopposed 
activation of RANK to varying degrees, resulting in 
enhanced osteoclastogenesis and consequently 
increased bone turnover.
54 
 
Mutations in the RANK gene (TNFRSF11A) that disrupt 
the signal peptide region of the protein result in the lack 
of normal cleavage of the signal peptide and an increase 
in RANK-mediated signaling. These activating mutations 
result in three different phenotypic presentations. 
 Early-onset Paget’s disease of bone (PDB2) is a 
heterogeneous, autosomal dominant skeletal disorder 
characterized by bone deformities, hearing deficits, 
and dental problems. PDB2 is due to an activating 
mutation in the RANK gene comprised of a 27-bp 
tandem duplication.
55
 
 Expansile skeletal hyperphosphatasia, an autosomal 
dominant disorder that presents with early onset of 
deafness, dental defects, and accelerated bone 
turnover manifested by pain in the bones and episodic 
hypercalcemia. Skeletal symptoms begin before 
puberty and progress with episodes of exacerbation 
until middle age. The activating mutation in the 
RANK gene is caused by 15-bp tandem duplication.
56
 
 Familial expansile osteolysis (FEO) is an autosomal 
dominant disorder that presents in early childhood to 
young adulthood with hearing deficit. Osteopenia is a 
common feature. The major skeletal finding in this 
disorder is osteolysis followed by bony expansion due 
to fat deposition rather than osteosclerosis. The 
genetic abnormality is an activating mutation in the 
RANK gene linked to an 18-bp tandem duplication. 
57
 
Furthermore, mutations of the sequestosome 1 gene 
(SQSTM1), which encodes an important scaffold protein 
in the NF-kB pathway, are a common cause of classical 
PDB. The rare syndrome of hereditary inclusion body 
myopathy, PDB, and fronto-temporal dementia is caused 
by mutations in the valosin containing protein (VCP) 
gene. This gene encodes VCP, which has a role in 
targeting the Ikβ (downstream molecule of this triad 
system) for degradation by the proteasome. 
58
 
Osteopetrosis. 
RANK, RANKL, OPG, as well as their signaling 
pathway may play a potential role in the pathogenesis of 
osteopetrosis. For instance, mice deficient in RANKL, 
RANK have shown severe osteopetrosis. Moreover, 
transgenic mice over expressing either OPG or soluble 
RANK both of which neutralize RANKL also have 
osteopetrosis.
13, 59
  
POTENTIAL THERAPEUTIC APPROACHES  
Monoclonal antibodies  
Denosumab is a fully human monoclonal antibody that 
avidly binds RANKL and blocks RANKL/RANK 
interaction and signaling. Unlike OPG, denosumab does 
not bind to TRAIL and hence considered to be beneficial 
for treatment of cancer metastasis to bone. Denosumab 
was approved by FDA in 2010 for the prevention of 
SREs from bone metastases in solid malignancies, as well 
as for the treatment of osteoporosis in postmenopausal 
women and men at high risk for fracture. This agent is 
administered subcutaneously with dose of 120 mg every 
4 weeks for the prevention of SREs, and with doses of 60 
mg every 6 months for its osteoporosis and bone loss 
indications. The mean half-life of denosumab is 
approximately 28 days.
60,61
 FDA approved denosumab, a 
new class of drugs that inhibit RANKL, for the treatment 
of patients whose GCTB is unresectable, or when surgery 
is likely to result in severe morbidity.
53
 
Osteoprotegerin like peptidomimetics  
Osteoprotegerin like peptidomimetics (e.g., OP3-4) are 
designed to block the RANKL/RANK interaction and to 
inhibit osteoclastic bone resorption. OP3-4 selectively 
inhibits RANKL but not TRAIL, and hence is effective in 
preventing malignant bone diseases. Refining the design 
of such peptides may improve efficacy and allow their 
use in both dissecting the relative importance of 
osteoprotegerin/RANKL interactions versus osteo-
protegerin/TRAIL interactions. This may lead to 
improved therapeutic approaches for treating myeloma 
and the associated bone disease. 
62
 
RANK receptor inhibitors 
Following identification of cytoplasmic motif of RANK 
involved in osteoclast differentiation, cell-permeable 
inhibitors termed the RANK receptor inhibitors (RRI), 
which target this motif were developed. The RRI peptide 
blocked RANKL-induced osteoclast formation from 
murine bone marrow derived macrophages. Furthermore, 
RRI inhibited the resorptive function of osteoclasts and 
induced osteoclast apoptosis. Treatment with the peptide 
impaired downstream signaling of RANK linked to Vav3, 
Rac1, and Cdc42 and resulted in disruptions of the actin 
cytoskeleton in differentiated osteoclasts. In addition, 
RRI blocked inflammation-induced bone destruction and 
protected against ovariectomy-induced bone loss in mice. 
These data may be useful in the development of selective 
therapeutic agents for the treatment of osteoporosis and 
other bone diseases.
63 
Novel peptide RANK antagonists 
It is an alternative approach to designing small peptides 
that able to specifically bind to the hinge region of 
membrane RANK responsible for the conformational 
change upon RANKL association. A nona peptide 
generated by this method was validated for its biological 
activity in vitro and in vivo and served as a lead 
compound for the generation of a series of peptide 
RANK antagonists derived from the original sequence. 
This novel, effective and affordable small peptide 
inhibitors specifically targets the receptor RANK and 
opens a new therapeutic opportunity for the treatment of 
resorptive bone disease.
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Ezymatic cleavage of RANK ectodomain  
Enteropeptidase can inhibit the RANKL-RANK 
signalling pathway through the cleavage of RANK. A 
surrogate peptide blocking assay indicated that 
enteropeptidase could specifically cleave RANK on the 
sequence NEEDK. Osteoclast differentiation assay and 
NF-κB activity assay confirmed that enteropeptidase 
could inhibit osteoclastogenesis in vitro through the 
cleavage of RANK.
65 
Selective Small Molecules 
Modulation of OPG in the bone micro environment can 
be as effective as exogenously administered OPG-Fc in 
inhibiting the growth of tumor deposits in bone and the 
periarticular resorption of adjuvant arthritis. Small 
molecules that selectively stimulate endogenous OPG 
expression could have therapeutic benefits similar to 
those of native OPG in reducing both the formation and 
the activity of osteoclasts. This could provide a new 
approach to development of drugs for treatment of 
diseases of increased bone resorption, such as 
osteoporosis, Paget’s disease, osteolytic bone metastases, 
hypercalcemia of malignancy, and rheumatoid arthritis.
66 
RANKL targeted peptides 
A novel peptide was designed from OPG with dual 
inhibitory activity against bone loss and inflammation 
using site-directed mutagenesis. Out of the three putative 
sites (i.e., Tyr70-Asp78, Tyr82-Glu96, and Leu113-
Arg122) available on OPG for RANKL binding, Leu113-
Arg122 was used as a template for peptide synthesis. 
Peptide mutants of the template sequence were 
synthesized and initially screened for their inhibitory 
effect on RANK-RANKL binding by competitive 
ELISA. The study provided a basis about the therapeutic 
benefit of this novel peptide in the prevention of bone 
loss and inflammation in rheumatoid arthritis with 
reduced side effects.
67 
RNA interference technology  
In the study conducted to assess the effect of inhibition of 
RANK expression in mouse bone marrow macrophages 
(BMM), three pairs of short hair pin RNAs (shRNA) 
targeting RANK were designed and synthesized. Among 
the three shRANKs examined, shRANK-3 significantly 
suppressed [88.3%] the RANK expression. shRANK-3 
also brought about a marked inhibition of osteoclast 
formation and bone resorption as demonstrated by tartrate 
resistant acid phosphatase (TRAP) staining and osteoclast 
resorption assay. The study showed that retrovirus-
mediated shRANK-3 suppresses osteoclast differentiation 
and osteolysis of BMMs in vitro.
68
 
Strontium ranelate 
Strontium ranelate is an oral daily drug formed of two 
atoms of stable strontium and an organic moiety (ranelic 
acid). Strontium ranelate combines the antiresorptive 
effect on bone with an additional anabolic action. In vitro 
studies have shown different effects of strontium ranelate 
on osteoblasts and osteoclasts. In the in vitro study 
conducted on osteoblasts, strontium ranelate induced a 
concentration-dependent increase in OPG mRNA 
expression as well as OPG secretion. On the other hand, 
RANKL mRNA and concentration were markedly 
decreased. The proposed mediator of these effects by 
Brennan et al was the calcium-sensing receptor. Indeed, 
knocking down the receptor abolished the effects of 
strontium ranelate on OPG and RANKL.
69
 
Chloroquine  
TRAF3 limits RANKL-induced osteoclastogenesis by 
suppressing canonical and non canonical NF-κB 
signaling. Conditional osteoclast -specific TRAF3-Knock 
out (cKO) mice had mild osteoporosis and increased 
osteoclast formation.  RANKL induced TRAF3 
degradation via the lysosome/autophagy system. The 
autophagy/lysosome inhibitor chloroquine reduced 
RANKL-induced osteoclast formation and function by 
increasing TRAF3 expression in OCPs in vitro and in 
vivo. Although chloroquine had no effect on basal bone 
resorption, it inhibited parathyroid hormone and 
ovariectomy-induced osteoclast activation in wild type 
mice.
70
 
Phytopharmaceuticals  
Jolkinolide B (JB) isolated from the root of Euphorbia 
fischeriana inhibited RANKL-induced OC differentiation 
from bone marrow macrophages (BMMs) without 
cytotoxicity. Furthermore, the expression of osteoclastic 
marker genes, such as tartrate-resistant acid phosphatase 
(TRAP), cathepsin K (CtsK), and calcitonin receptor 
(CTR), was significantly inhibited. JB inhibited RANKL-
induced activation of NF-κB by suppressing RANKL-
mediated IκBα degradation. Moreover, JB inhibited 
RANKL-induced phosphorylation of mitogen-activated 
protein kinases (p38, JNK, and ERK). It is identified that 
JB as an inhibitor of osteoclast formation and provides 
evidence that JB might be an alternative medicine for 
preventing and treating osteolysis.
71
  Bone  protective  
effect of  water  extract  of  the  stem  of  Acer  
tegmentosum  (WEAT) was also investigated. It was 
found that WEAT inhibits osteoclast differentiation 
induced by RANKL. In osteoclast precursor cells,  
WEAT  inhibited  RANKL-induced  activation  of  JNK,  
NF-κB,  and cAMP  response  element-binding protein 
(CREB), leading  to  suppression  of  the  induction  of  c-
Fos  and  NFATc1,  key  transcription  factors  for  
osteoclast  differentiation. In addition, WEAT inhibited 
bone resorbing activity of mature osteoclasts.  
Furthermore,  the  oral  administration  of  WEAT  
reduced RANKL-induced bone  resorption  and 
trabecular  bone loss in  mice in vivo.
72 
CONCLUSION AND FUTURE PERSPECTIVES  
The role of RANK/RANKL/OPG system in metabolic 
bone disorders is well emphasized in this review. 
RANK/RANKL/OPG molecular triad can be a hot spot as 
a therapeutic device in the areas of bone metabolic 
diseases and oncology. This system has shown a 
significant contribution on the pathogenesis of various 
types of osteoporosis, primary malignant bone tumors, 
rare genetic disorders as well as arthritis. Bone 
degradation by osteoclasts plays a crucial role in bone 
tumor development and control of local osteoclast 
activity. This can provide a potential therapeutic strategy 
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targeting the RANK/RANKL/OPG triad system via 
different pathways, mainly blocking vicious cycle which 
resides between bone degradation and growth of tumor 
cells. Such therapies may be used in combined setting 
with conventional therapeutic approaches. In general, the 
RANK/RANKL/OPG triad and its signaling hold a great 
promise for the treatment of bone metabolic disorders and 
malignant tumors. Further studies are needed to 
determine orchestrated effects of this system by 
inhibiting osteoclast activity, tumor migration and 
immunomodulation 
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